United States Patent (19) 11 Patent Number: 6,057,107 Fulton (45) Date of Patent: May 2, 2000

Total Page:16

File Type:pdf, Size:1020Kb

United States Patent (19) 11 Patent Number: 6,057,107 Fulton (45) Date of Patent: May 2, 2000 US006057107A United States Patent (19) 11 Patent Number: 6,057,107 Fulton (45) Date of Patent: May 2, 2000 54 METHODS AND COMPOSITIONS FOR OTHER PUBLICATIONS FLOW CYTOMETRIC DETERMINATION OF DNA SEQUENCES N N Ref. #12: Human Genetics v 93:351-2 (1994) “Two CA/GT repeat polymorphisms in intron 27 of the human neurofi 75 Inventor: R. Jerrold Fulton, Cedar Hill, Tex. bromatosis type 1 (NF1) gene" Lazaro et al. Ref. #14: Human Mutatation v. 3:12-18 (1994) “Exon Eight 73 Assignee: Luminex Corporation, Austin, Tex. APC Mutations Account for a Disproportionate Number of Familial Adenomatous Polyposis Families”, Koorey et al. 21 Appl. No.: 09/055,329 Ref. #15: Human Molecular Genetics v. 2:1307-8 (1993) “A y - - - 9 missense mutation in exon 4 of the human adenosine deami 22 FilledCC ADr.pr: o,6, 1998 nase gene causes Severe combinedbined iimmunodeficiency', defici AtaA Soy et al. Related U.S. Application Data Ref. #19: Human Genetics v. 84:228-232 (1990) “Rapid detection of deletions in the Duchenne muscular dystrophy 63 Continuation of application No. 08/542,401, Oct. 11, 1995, gene by PCR amplification of deletion-prone exon Pat. No. 5,736,330. Sequences”, Hentemann et al. (51) Int. Cl." ....................................................... C12O 1/68 Ref. #20: Genomics v. 18:673–679 (1993) “Genomic Orga 52 U.S. Cl. ............................. 435/6, 435/91.1; 435/91.2 nization and Transcriptional Units at the Myotonic Dystro 58 Field of Search ................................ 422/68.1; 435/6, phy Locus", Shaw et al. 435/91.1, 91.2; 935/77, 78 Ref. #21: Science v.256:784-789 (1992), “Triplet Repeat Mutations in Human Disease”, Caskey et al. 56) References Cited (List continued on next page.) U.S. PATENT DOCUMENTS Primary Examiner Ardin H. Marschel 4,661,913 4/1987 Wu et al. ................................ 364/500 Attorney, Agent, or Firm-Gilberto M. Villacorta; Pepper 4,665,020 5/1987 Saunders ...... ... 435/7 Hamilton LLP 4,673,288 6/1987 Thomas et al. ........................... 356/72 4,676,640 6/1987 Briggs .............. ... 356/317 (57) ABSTRACT 4,710,021 12/1987 Von Behrens ............................. 356/72 4,713,348 12/1987 Ullman ............. ... 436/501 A method for the analysis of DNA sequences and PCR 4,767,205 8/1988 Schwartz et al. ......................... 356/71 products comprises the steps of constructing an 4,778,593 10/1988 Yamashita et al. .. 209/3.1 oligonucleotide-labeled beadset, and labeled complemen 4,857,451 8/1989 Schwartz .............. ... 435/7 tary probe, and exposing the beadset and probe to a DNA 4,868,104 9/1989 Kurn et al..... ... 435/6 fragment or PCR product under hybridizing conditions and 4,884,886 12/1989 Salzman et al. ... 356/367 analyzing the combined Sample/beadset by flow cytometry. 4,887,721 12/1989 Martin et al. ... ... 209/579 4,905,169 2/1990 Buican et al. ... ... 364/525 Flow cytometric measurements are used to classify beads 4,918,004 4/1990 Schwartz ..................................... 435/7 within an exposed beadset to determine the presence of 5,028,545 7/1991 Soini ............ ... 436/5O1 identical or nonidentical Sequences within the test Sample. 5,093,234 3/1992 Schwartz ................................ 435/7.21 The inventive technology enables the rapid analysis of DNA 5,107,422 4/1992 Kamentsky et al. ... 364/413.08 Sequences and detection of point mutations, deletions and/or 5,127,730 7/1992 Brelje et al. ......... ... 356/318 inversions while also reducing the cost and time for per 5,149,661 9/1992 Gjerde et al. ............ ... 436/178 forming genetic assayS. 5,150,313 9/1992 van den Engh et al. ............... 364/569 (List continued on next page.) 27 Claims, 3 Drawing Sheets 10 pmol DOUBLE STRANDED 60 COMPETITOR PARTICLES/ CHANNEL 30 WILD TYPE LOG (MEASURED INTENSITY) 6,057,107 Page 2 U.S. PATENT DOCUMENTS Cantarero et al., “The Adsorptive Characteristics of Proteins 5,156,810 10/1992 Ribi...................................... 422/82.01 for Polystyrene and Their Significance in Solid-Phase 5,199,576 4/1993 Corio et al. ... ... 209/564 Immunoassays,” Analytical Biochemistry, 105, 375–382 5,204.884 4/1993 Leary et al. .............................. 377/10 (1980). 5,219,763 6/1993 Van Hoegaerden . ... 436/523 5,224,058 6/1993 Michaels et al. ..... ... 364/554 Colvin et al., “The Covalent Binding of Enzymes and 5,273,881 12/1993 Sena et al. .................................. 425/6 Immunoglobulins to Hydrophilic Microspheres” in Micro 5,286,452 2/1994 Hansen ...................................... 422/73 spheres: Medical and Biological Applications, 1-13, CRC, 5,319,079 6/1994 Reddy et al. ........................ 536/25.32 5,326,692 7/1994 Brinkley et al. ............................ 435/6 Boca Raton, FL, 1988. 5,367,474 11/1994 Auer et al. ........ ... 364/555 5,380,663 1/1995 Schwartz et al. ......................... 436/10 Fisher, “The Use of Multiple Measurements in Taxonomic 5,385,822 1/1995 Melnicoff et al. .......................... 435/5 Problems,” Annals of Eugenics, 7, 179-188 (1936). 5,393,673 2/1995 Gjerde ..................................... 436/171 5,401,847 3/1995 Glazer et al. ... 546/107 Fulwyler et al., “Flow Microsphere Immunoassay for the 5,403,711 4/1995 Walder et al. .............................. 435/6 Quantitative and Simultaneous Detection of Multiple 5,405,784 4/1995 Van Hoegaerden . 436/523 Soluble Analytes,” Methods in Cell Biology, 33, 613-629 5,408,307 4/1995 Yamamoto et al. ...................... 356/73 (1990). 5,413.907 5/1995 Worton et al. ... ... 435/6 5,429,923 7/1995 Seidman et al. .. ... 435/6 Goss et al., “Major Histocompatibility Complex-specific 5,736,330 4/1998 Fulton ......................................... 435/6 Prolongation of Murine Skin and Cardiac Allograft Survival after In Vivo Depletion of VB". T Cells,” The Journal of OTHER PUBLICATIONS Experimental Medicine, 177, 35–44 (1993). Ref. ii.22a: Human Molecular Genetics v. 2:1713–1715 (1993) “Analysis of the huntingtin gene reveals a trinucle Horan et al., “Fluid Phase Particle Fluorescence Analysis: otide-length polymorphism in the region of the gene that Rheumatoid Factor Specificity Evaluated by Laser Flow contains two CCG-rich stretches and a correlation between Cytophotometry” in Immunoassays in the Clinical Labora decreased age of onset of Huntington's disease and CAG tory, 185-198 (Liss 1979). repeat number, Rubinsztein et al. Illum et al., “Attachment of Monoclonal Antibodies to Ref. ii.22b: Molecular and Cellular Probes v. 7:235–239 Microspheres,” Methods in Enzymology, 112, 67-84 (1993) “A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on (1985). Huntington's disease chromosomes, Warner et al. Lindmo et al., “Immunometric Assay by Flow Cytometry Ref. #22c: Cell v. 74:971–983 (1993) “A novel Gene Con Using Mixtures of Two Particle Types of Different Affinity,” taining a Trinucleotide Repeat That IS Expanded and Journal of Immunological Methods, 126, 183-189 (1990). Unstable on Huntington's Disease Chromosomes’, Mac McHugh, “Flow Microsphere Immunoassay for the Quan Donald et al. titative and Simultaneous Detection of Multiple Soluble Ref. #23: Genomics v. 7:235–244 (1990) “Multiplex DNA Analytes,” in Methods in Cell Biology, 42, Part B, 575-595 Delection Detetion and EXOn Sequencing of the Hypoxn thine Phosphoribosyltransferase Gene in Lesch-Nyhan (Academic Press 1994). Famailies', Gibbs et al. McHugh et al., “Microsphere-Based Fluorescence Immu Ref. #24: Human Mutation v. 1:303-309 (1992) “A Muta noassays Using Flow Cytometry Instrumentation,” in Clini tion Common in Non-Jewish Tay-Sachs Disease: Fre cal Flow Cytometry Ed. K. D. Bauer, et al., Williams and quency and RNA Studies', Akerman et al. Williams, Baltimore, MD, 1993, 535-544. Ref. #25: Proceedings of the National Academy of Sciences McHugh, “Flow Cytometry and the Application of Micro v. 90:4552–4556 (1993) “Mutations in the CYP11B1 gene Sphere-Based Fluorescence Immunoassays, Immu causing congenital adrenal hyperplasia and hypertension nochemica, 5, 1-6 (1991). cluster in exons 6, 7 and 8”, Curnow et al. Ref. #26a: Nucleic Acids Research v. 20:1443 (1992) PCR Saiki et al., “Genetic Analysis of Amplified DNA with detetion of the insertion/delection polymorphism of the Immobilized Sequence-Specific Oligonucleotide Probes.” human angiotensin converting enzyme gene (DCP1) (dipep Proceedings of the National Academy of Sciences of the tidyl carboxypeptidase 1), Rigat et al. United States of America, 86, 6230–6234 (1989). Ref. #26b: Biochemical and Biophysical Research Commu Vener et al., “A Novel Approach to Nonradioactive Hybrid nication v. 184:9-15 (1992) “Association of a Polymor ization Assay of Nucleic Acids. Using Stained Latex Par phism of the Angiotensin I-Converting Enzyme Gene With ticles,” Analytical Biochemistry, 198, 308-311 (1991). ESSential Hypertension', Zee et al. Ref. #32: Leukemia v. 8:186–189 (1994) “An Optimized Vlieger et al., “Quantitation of Polymerase Chain Reaction Multiplex Polymerase Chain Reaction (PCR) for Detection Products by Hybridization-Based Assays with Fluorescent, of BCR-ABL Fusion mRNAS in Haematological Disor Colorimetric, or Chemiluminescent Detection,” Analytical ders’, Cross et al. Biochemistry, 205, 1–7 (1992). Bottema et al., “PCR Amplification of Specific Alleles: Wilson et al., “A New Microsphere-Based Immunofluores Rapid Detection of Known Mutations and Polymorphisms,” cence Assay Using Flow Cytometry,” Journal of Immuno Mutation Research, 288,93–102 (1993). logical Methods, 107, 225-230 (1988). U.S. Patent May 2, 2000 Sheet 1 of 3 6,057,107 10 pmol DOUBLE STRANDED 60 COMPETITOR PARTICLES/ CHANNEL 30 S d S. m WILD TYPE O ASEA NO COMPETITOR LOG (MEASURED INTENSITY) FIG. 1A 100 pmol DOUBLESTRANDED COMPETITOR 60 PARTICLES/ CHANNEL 30 SE WILD TYPE ... I POINT MUTANT O NO COMPETITOR LOG (MEASURED INTENSITY) FIG. 1B U.S. Patent May 2, 2000 Sheet 2 of 3 6,057,107 60 1000 pmol DOUBLESTRANDED COMPETITOR PARTICLES/ CHANNEL 30 WILDTYPE POINT MUTANT NO COMPETITOR LOG (MEASURED INTENSITY) FIG.
Recommended publications
  • Hereditary Spherocytosis: Clinical Features
    Title Overview: Hereditary Hematological Disorders of red cell shape. Disorders Red cell Enzyme disorders Disorders of Hemoglobin Inherited bleeding disorders- platelet disorders, coagulation factor Anthea Greenway MBBS FRACP FRCPA Visiting Associate deficiencies Division of Pediatric Hematology-Oncology Duke University Health Service Inherited Thrombophilia Hereditary Disorders of red cell Disorders of red cell shape (cytoskeleton): cytoskeleton: • Mutations of 5 proteins connect cytoskeleton of red cell to red cell membrane • Hereditary Spherocytosis- sphere – Spectrin (composed of alpha, beta heterodimers) –Ankyrin • Hereditary Elliptocytosis-ellipse, elongated forms – Pallidin (band 4.2) – Band 4.1 (protein 4.1) • Hereditary Pyropoikilocytosis-bizarre red cell forms – Band 3 protein (the anion exchanger, AE1) – RhAG (the Rh-associated glycoprotein) Normal red blood cell- discoid, with membrane flexibility Hereditary Spherocytosis: Clinical features: • Most common hereditary hemolytic disorder (red cell • Neonatal jaundice- severe (phototherapy), +/- anaemia membrane) • Hemolytic anemia- moderate in 60-75% cases • Mutations of one of 5 genes (chromosome 8) for • Severe hemolytic anaemia in 5% (AR, parents ASx) cytoskeletal proteins, overall effect is spectrin • fatigue, jaundice, dark urine deficiency, severity dependant on spectrin deficiency • SplenomegalSplenomegaly • 200-300:million births, most common in Northern • Chronic complications- growth impairment, gallstones European countries • Often follows clinical course of affected
    [Show full text]
  • MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002
    MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002 Michigan Department of Community Health Community Public Health Agency and Center for Health Statistics 3423 N. Martin Luther King Jr. Blvd. P. O. Box 30691 Lansing, Michigan 48909 Michigan Department of Community Health James K. Haveman, Jr., Director B-274a (March, 2002) Authority: P.A. 236 of 1988 BIRTH DEFECTS REGISTRY MICHIGAN DEPARTMENT OF COMMUNITY HEALTH BIRTH DEFECTS REGISTRY STAFF The Michigan Birth Defects Registry staff prepared this manual to provide the information needed to submit reports. The manual contains copies of the legislation mandating the Registry, the Rules for reporting birth defects, information about reportable and non reportable birth defects, and methods of reporting. Changes in the manual will be sent to each hospital contact to assist in complete and accurate reporting. We are interested in your comments about the manual and any suggestions about information you would like to receive. The Michigan Birth Defects Registry is located in the Office of the State Registrar and Division of Health Statistics. Registry staff can be reached at the following address: Michigan Birth Defects Registry 3423 N. Martin Luther King Jr. Blvd. P.O. Box 30691 Lansing MI 48909 Telephone number (517) 335-8678 FAX (517) 335-9513 FOR ASSISTANCE WITH SPECIFIC QUESTIONS PLEASE CONTACT Glenn E. Copeland (517) 335-8677 Cytogenetics Laboratory Reporting Instructions I. INTRODUCTION This manual provides detailed instructions on the proper reporting of diagnosed birth defects by cytogenetics laboratories. A report is required from cytogenetics laboratories whenever a reportable condition is diagnosed for patients under the age of two years.
    [Show full text]
  • Hereditary Spherocytosis
    Hereditary Spherocytosis o RBC band 3 protein testing is a very sensitive and Indications for Ordering specific test for the diagnosis of hereditary Use to confirm diagnosis of hereditary spherocytosis when spherocytosis hemolytic anemia and spherocytes are present Physiology • RBC band 3 protein is a major structural protein of RBCs Test Description o Reduction in the amount of band 3 fluorescence after Test Methodology binding with EMA correlates with spherocytosis • Red blood cell (RBC) surface protein band 3 staining with Genetics eosin-5-maleimide (EMA) analyzed by flow cytometry Clinical Validation Genes: ANK1, EPB42, SLC4A1, SPTA1, SPTB • Validated against the clinical diagnosis of hereditary Inheritance spherocytosis supported by osmotic fragility and/or • Autosomal dominant: 75% molecular testing • Autosomal recessive: 25% Tests to Consider Penetrance: variable Structure/Function Primary Test • Chromosomal location: 17q21.31 RBC Band 3 Protein Reduction in Hereditary Spherocytosis • Provides structure for the red cell cytoskeleton 2008460 • Use to confirm diagnosis of hereditary spherocytosis Test Interpretation when hemolytic anemia and spherocytes are present Sensitivity/Specificity Related Test • Clinical sensitivity: 93% Osmotic Fragility, Erythrocyte 2002257 • Analytical sensitivity/specificity: unknown • Functional testing of RBC sensitivity to osmotic stress Results Disease Overview • Normal o Normal staining of band 3 protein with EMA does not Prevalence: 1/2,000 in northern Europeans suggest hereditary spherocytosis
    [Show full text]
  • Genetic Disorder
    Genetic disorder Single gene disorder Prevalence of some single gene disorders[citation needed] A single gene disorder is the result of a single mutated gene. Disorder Prevalence (approximate) There are estimated to be over 4000 human diseases caused Autosomal dominant by single gene defects. Single gene disorders can be passed Familial hypercholesterolemia 1 in 500 on to subsequent generations in several ways. Genomic Polycystic kidney disease 1 in 1250 imprinting and uniparental disomy, however, may affect Hereditary spherocytosis 1 in 5,000 inheritance patterns. The divisions between recessive [2] Marfan syndrome 1 in 4,000 and dominant types are not "hard and fast" although the [3] Huntington disease 1 in 15,000 divisions between autosomal and X-linked types are (since Autosomal recessive the latter types are distinguished purely based on 1 in 625 the chromosomal location of Sickle cell anemia the gene). For example, (African Americans) achondroplasia is typically 1 in 2,000 considered a dominant Cystic fibrosis disorder, but children with two (Caucasians) genes for achondroplasia have a severe skeletal disorder that 1 in 3,000 Tay-Sachs disease achondroplasics could be (American Jews) viewed as carriers of. Sickle- cell anemia is also considered a Phenylketonuria 1 in 12,000 recessive condition, but heterozygous carriers have Mucopolysaccharidoses 1 in 25,000 increased immunity to malaria in early childhood, which could Glycogen storage diseases 1 in 50,000 be described as a related [citation needed] dominant condition. Galactosemia
    [Show full text]
  • Bibliography of Human Genetics*
    BIBLIOGRAPHY OF HUMAN GENETICS* R. H. POST Department of Human Genetics, University of Michigan Medical School, Ann Arbor, Michigan Selections from the Current List of Medical Literature through February, 1959 and other sources 296. AGER, J. A., LEHMANN, H., & VELLA, F. 1958. Haemoglobin Norfolk: a new haemoglobin found in an English family with observations on the naming of new haemoglobin variants Brit. M. J. 5095: 539-541. 297. ALEXANDER, J. O., & GRANT, P. W. 1958. Monilethrix; report of three cases with family his- tory. Scot. M. J. 3(8): 356-360. 298. ALLAN, J. D., CUSWORTH, D. C., DENT, C. E., & WILSON, V. K. 1958. A disease, probably hereditary, characterized by severe mental deficiency and a constant gross abnormality of aminoacid metabolism. Lancet, Lond. 1(7013): 182-187. 299. ALLISON, A. C. 1958. The genetical and clinical significance of the haptoglobins. Proc. R. Soc. Ml., Lond. 51(8): 641-645. 300. ALLISON, A. C., & BLUMBERG, B. S. 1958. Familial osteoarthropathy of the fingers. J. Bonc Surg. Brit. VZol. 40-B(3): 538-545. 301. ALLORI, L., & VITAMIA, P. 1958. Osservazioni genetistiche su 44 casi di cardiopatie acquisite. [Genetic observations on 44 cases of acquired heart disease] Acta genet. med. gemellol., Roma 7(3): 397-410. 302. AMYOT, R. 1958. L'Audi-mutite; document clinique portant sur trios membres (lune meme fratrie. [Audimutitas; clinical observation on three members of the same family] Presse med. 66(56): 1289-1292. 303. ANASTASI, A. 1958. Heredity, environment, and the question how? Psychol. Rev. 65(4): 197-208. 304. ANDERSEN, J. 1958. Modifying influence of the secretor gene on the development of the ABH substance; a contribution to the conception of the Lewis group system.
    [Show full text]
  • Blueprint Genetics Comprehensive Hematology and Hereditary Cancer
    Comprehensive Hematology and Hereditary Cancer Panel Test code: HE1401 Is a 348 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of hematological disorder with genetic predisposition to malignancies. This panel is designed to detect heritable germline mutations and should not be used for the detection of somatic mutations in tumor tissue. Is not recommended for patients suspected to have anemia due to alpha-thalassemia (HBA1 or HBA2). These genes are highly homologous reducing mutation detection rate due to challenges in variant call and difficult to detect mutation profile (deletions and gene-fusions within the homologous genes tandem in the human genome). Is not recommended for patients with a suspicion of severe Hemophilia A if the common inversions are not excluded by previous testing. An intron 22 inversion of the F8 gene is identified in 43%-45% individuals with severe hemophilia A and intron 1 inversion in 2%-5% (GeneReviews NBK1404; PMID:8275087, 8490618, 29296726, 27292088, 22282501, 11756167). This test does not detect reliably these inversions. Is not recommended for patients suspected to have anemia due to alpha-thalassemia (HBA1 or HBA2). These genes are highly homologous reducing mutation detection rate due to challenges in variant call and difficult to detect mutation profile (deletions and gene-fusions within the homologous genes tandem in the human genome). About Comprehensive Hematology and Hereditary Cancer Inherited hematological diseases are a group of blood disorders with variable clinical presentation. Many of them predispose to malignancies and for example patients with inherited bone marrow failure syndromes (Fanconi anemia) have a high risk of developing cancer, either leukemia or solid tumors.
    [Show full text]
  • Blood Lab First Week
    Blood Lab First Week This is a self propelled powerpoint study atlas of blood cells encountered in examination of the peripheral blood smear. It is a requirement of this course that you begin review of these slides with the first day of class in order to familiarize yourself with terms used in describing peripheral blood morphology. Laboratory final exam questions are derived directly from these slides. The content of these slides may duplicate slides (1-37) listed on the Hematopathology Website. You must familiarize yourself with both sets of slides in order to have the best learning opportunity. Before Beginning This Slide Review • Please read the Laboratory information PDF under Laboratory Resources file to learn about – Preparation of a blood smear – How to select an area of the blood smear for review of morphology and how to perform a white blood cell differential – Platelet estimation – RBC morphology descriptors • Anisocytosis • Poikilocytosis • Hypochromia • Polychromatophilia Normal blood smear. Red blood cells display normal orange pink cytoplasm with central pallor 1/3-1/2 the diameter of the red cell. There is mild variation in size (anisocytosis) but no real variation in shape (poikilocytosis). To the left is a lymphocyte. To the right is a typical neutrophil with the usual 3 segmentations of the nucleus. Med. Utah pathology Normal blood: thin area Ref 2 Normal peripheral blood smear. This field is good for exam of cell morphology, although there are a few minor areas of overlap of red cells. Note that most cells are well dispersed and the normal red blood cell central pallor is noted throughout the smear.
    [Show full text]
  • Hereditary Spherocytosis Recent Experience and Current Concepts Ofpathophysiology
    Hereditary Spherocytosis Recent Experience and Current Concepts ofPathophysiology ROBERT D. CROOM III, M.D.* CAMPBELL W. MCMILLAN, M.D.t GEORGE F. SHELDON, M.D.* EUGENE P. ORRINGER, M.D.t Hereditary spherocytosis is a clinically heterogeneous, geneti- From the Departments of Surgery,* Pediatrics,t and cally determined red blood cell membrane disorder resulting in Medicine,f The University of North Carolina School of hemolytic anemia. A deficiency of spectrin, the largest and most Medicine and the North Carolina Memorial Hospital, abundant structural protein of the erythrocyte membrane skel- Chapel Hill, North Carolina eton, results in the formation of spherocytes which lack the strength, durability, and flexibility to withstand the stresses of the circulation. Clinical manifestations of the disease are pri- marily dependent on the severity of hemolysis, which additionally The membrane defect resulting in the shortened sur- results in an increased incidence of pigment gallstones. The like- vival of erythrocytes in HS has been found to be a defi- lihood of cholelithiasis is directly related to patient age and is ciency in spectrin, the largest and most abundant struc- uncommon before 10 years of age. Splenectomy is indicated in tural protein of the red cell membrane skeleton.3'4 virtually every patient. When the disease is diagnosed in early childhood, the risk of overwhelming postsplenectomy sepsis Thought to be responsible for the shape, strength, and makes it advisable to delay splenectomy until after 6 years of reversible deformability of the red cell, the membrane age if possible. At the time of splenectomy, it is important to skeleton provides the flexibility and durability necessary identify and remove any accessory spleens.
    [Show full text]
  • ED368492.Pdf
    DOCUMENT RESUME ED 368 492 PS 6-2 243 AUTHOR Markel, Howard; And Others TITLE The Portable Pediatrician. REPORT NO ISBN-1-56053-007-3 PUB DATE 92 NOTE 407p. AVAILABLE FROMMosby-Year Book, Inc., 11830 Westline Industt.ial Drive, St. Louis, MO 63146 ($35). PUB TYPE Guides Non-Classroom Use (055) Reference Materials Vocabularies/Classifications/Dictionaries (134) Books (010) EDRS PRICE MF01/PC17 Plus Postage. DESCRIPTORS *Adolescents; Child Caregivers; *Child Development; *Child Health; *Children; *Clinical Diagnosis; Health Materials; Health Personnel; *Medical Evaluation; Pediatrics; Reference Materials; Symptoms (Individual Disorders) ABSTRACT This ready reference health guide features 240 major topics that occur regularly in clinical work with children nnd adolescents. It sorts out the information vital to successful management of common health problems and concerns by presentation of tables, charts, lists, criteria for diagnosis, and other useful tips. References on which the entries are based are provided so that the reader can perform a more extensive search on the topic. The entries are arranged in alphabetical order, and include: (1) abdominal pain; (2) anemias;(3) breathholding;(4) bugs;(5) cholesterol, (6) crying,(7) day care,(8) diabetes, (9) ears,(10) eyes; (11) fatigue;(12) fever;(13) genetics;(14) growth;(15) human bites; (16) hypersensitivity; (17) injuries;(18) intoeing; (19) jaundice; (20) joint pain;(21) kidneys; (22) Lyme disease;(23) meningitis; (24) milestones of development;(25) nutrition; (26) parasites; (27) poisoning; (28) quality time;(29) respiratory distress; (30) seizures; (31) sleeping patterns;(32) teeth; (33) urinary tract; (34) vision; (35) wheezing; (36) x-rays;(37) yellow nails; and (38) zoonoses, diseases transmitted by animals.
    [Show full text]
  • Genomic Features Defining Exonic Variants That Modulate Splicing Adam Woolfe1*, James C Mullikin2, Laura Elnitski1*
    Woolfe et al. Genome Biology 2010, 11:R20 http://genomebiology.com/2010/11/2/R20 RESEARCH Open Access Genomic features defining exonic variants that modulate splicing Adam Woolfe1*, James C Mullikin2, Laura Elnitski1* Abstract Background: Single point mutations at both synonymous and non-synonymous positions within exons can have severe effects on gene function through disruption of splicing. Predicting these mutations in silico purely from the genomic sequence is difficult due to an incomplete understanding of the multiple factors that may be responsible. In addition, little is known about which computational prediction approaches, such as those involving exonic splicing enhancers and exonic splicing silencers, are most informative. Results: We assessed the features of single-nucleotide genomic variants verified to cause exon skipping and compared them to a large set of coding SNPs common in the human population, which are likely to have no effect on splicing. Our findings implicate a number of features important for their ability to discriminate splice- affecting variants, including the naturally occurring density of exonic splicing enhancers and exonic splicing silencers of the exon and intronic environment, extensive changes in the number of predicted exonic splicing enhancers and exonic splicing silencers, proximity to the splice junctions and evolutionary constraint of the region surrounding the variant. By extending this approach to additional datasets, we also identified relevant features of variants that cause increased exon inclusion and ectopic splice site activation. Conclusions: We identified a number of features that have statistically significant representation among exonic variants that modulate splicing. These analyses highlight putative mechanisms responsible for splicing outcome and emphasize the role of features important for exon definition.
    [Show full text]
  • Pathology Course
    Pathology Course Kindly Sponsored by: Edited by: Michelle Kunc, Jhia Teh, Sally Barker and Yvonne Tsitsiou 1 Introduction The Medical Education Society (MedED) was established in 2004 by three students who were keen to develop schemes whereby senior students tutor younger ones - ‘peer-to- peer’ learning. It was decided that teaching would be outside the formal curriculum and the topics covered would reflect learning needs identified by members of the society and student body. This year we have coordinated PACES and Pathology revision courses, which are being delivered by past ICSM students. We hope you enjoy our Year 5 events and find their content useful for your revision. We would like to thank all the doctors involved in the production of this guide for their support and for taking time out of the schedules to come back and teach us. We would also like to thank the previous MedED guide editors: • 2016-2017: Daniel Campioni-Norman, Rhys Smith, Helen-Cara Younan and Rebekah Judge • 2017-2018: Charlie Caird, Stephanie EzeKwe, Mohammad Fallaha, Samyukta Sundar • 2018-2019: Sophia von Widekind, Lasith Ranasinghe, Daniel Huddart, Alex Huddart If you have any questions please contact us at medical.education@imperial.ac.uk. Please note: MedED does not represent the ICSM Faculty or Student Union. This guide has been produced by students and the Pathology Course lecturers. We have made every effort to ensure that the following information is accurate and reliable. However, this guide should not be used to replace formal ICSM teaching and education
    [Show full text]
  • Differential Diagnosis of Hereditary Hemolytic Anemias in a Single Multiscreening Test by TGA/Chemometrics
    Electronic Supplementary Material (ESI) for Chemical Communications. This journal is © The Royal Society of Chemistry 2020 Differential diagnosis of hereditary hemolytic anemias in a single multiscreening test by TGA/Chemometrics Roberta Risolutia, Patrizia Caprarib, Giuseppina Gullifaa, Francesco Sorrentinoc, Laura Maffeic , Sara Massimib, Elena Carcassiaand Stefano Materazzia* aDepartment of Chemistry, “Sapienza” University of Rome, p.le A.Moro 5, 00185 Rome Italy b National Centre for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy c Thalassemia Unit, S. Eugenio Hospital, Piazzale dell’Umanesimo 10, 00144 Rome, Italy Results and discussion Hematological characterization Patients were classified by evaluating the characteristic features for hemolytic anemias due to hemoglobinopathies and membrane defects. Table S1 shows the hematological data expressed as mean ± standard deviation (SD) while the comparison among groups was performed by the analysis of variance (ANOVA) followed by the Tukey test to assess significances among classes. The group of HS/HE patients showed a moderate hemolytic anemia with significantly decrease in RBC, Hb and Hct values, and a significant increase in RDW values, in comparison with healthy subjects. The patients were carriers of anomalies of the main erythrocyte membrane proteins such as spectrin, protein Band 3 and protein 4.1.The thalassemia patient group included patients with Thalassemia intermedia and major both transfusion dependent and not transfused, who had a very heterogeneous degree of clinical severity. The hematological parameters were significantly different from those of healthy individuals and HS/HE with a decrease in RBC, Hb, Hct, MCV, and MCH and a significant increase in RDW.
    [Show full text]